Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
HFA 23: DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF
Author(s): Ross Campbell Added: 1 year ago
ESC-HFA 23 –Dr Ross Campbell (University of Glasgow, UK)joins us onsite to discuss the findings of the DAPA-RESIST Trial, which aimed to assess the affect of dapagliflozin as compared to metolazone in heart failure patients with diuretic resistance (NCT04860011). In this phase 3 trial, investigators studied whether SGLT2i led to greater diuresis in this patient group, as to the standard practice… View more

Heart Failure
Resistant Hypertension: An Overview
Author(s): Giacomo Buso , Claudia Agabiti-Rosei , Matteo Lemoli , et al Added: 10 months ago

Prevention & Chronic Conditions
Yield and Characterisation of CFT in ANOCA
Author(s): Johanna McChord , Astrid Hubert , Udo Sechtem , et al Added: 6 months ago

Prevention & Chronic Conditions
Updates on Chronic Coronary Syndrome
Author(s): Filippo Gurgoglione , Giampaolo Niccoli Added: 5 months ago

Prevention & Chronic Conditions

CV Disease in Special Populations
Separated Vasoreactivity Testing of ACH
Author(s): Shozo Sueda , Tomoki Sakaue Added: 7 months ago

Prevention & Chronic Conditions
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 month ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions
Perfect Vasoreactivity Test
Author(s): Shozo Sueda , Tomoki Sakaue Added: 8 months ago

Prevention & Chronic Conditions

Intervention
Angela Maas
Research Area(s) / Expertise:
Angela Maas has been a cardiologist since 1988, specialising in heart disease in women. She holds a chair in cardiology for womenat Radboud University in Nijmegen, the Netherlands. The main focus of her work is cardiac symptoms in women at middle-age and the role of female-specific risk factors in (early) heart disease. She also founded an expert centre for microvascular coronary disease at the… View more
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi
Author(s): Harriette Van Spall , James L Januzzi Added: 1 year ago
ESC-HFA 2023 – Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss late-breaking science highlights of this year's ESC Heart Failure. Trials covered in details include: 1:13: First-in-Human Study of NI006 in Patients With Amyloid Transthyretin Cardiomyopathy 1:42: TRACER-HF:Trientine-HCL for treatment of… View more

Guidelines & Statements

Heart Failure
Coronary Spasm: Ethnic and Sex Differences
Author(s): Peter Ong , Astrid Hubert , Maike Schwidder , et al Added: 1 year ago

Demographic

CV Disease in Special Populations